151 related articles for article (PubMed ID: 36754935)
21. Prostate Cancer Imaging with 18F-Fluciclovine.
Savir-Baruch B; Schuster DM
PET Clin; 2022 Oct; 17(4):607-620. PubMed ID: 36229104
[TBL] [Abstract][Full Text] [Related]
22. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
[No Abstract] [Full Text] [Related]
23. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.
Chen B; Wei P; Macapinlac HA; Lu Y
Nucl Med Commun; 2019 Sep; 40(9):940-946. PubMed ID: 31343613
[TBL] [Abstract][Full Text] [Related]
25. 18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma.
Bogsrud TV; Londalen A; Brandal P; Leske H; Panagopoulos I; Borghammer P; Bach-Gansmo T
Clin Nucl Med; 2019 Aug; 44(8):605-611. PubMed ID: 31274605
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer.
Hoekstra RJ; Beulens A; Vrijhof EHJEJ; Wyndaele DNJ; Roef M; Brouwer LJM; Somford DM; Sedelaar M; van Basten JA
Nucl Med Commun; 2021 May; 42(5):476-481. PubMed ID: 33323869
[TBL] [Abstract][Full Text] [Related]
27. [
Zanoni L; Bianchi L; Nanni C; Pultrone C; Giunchi F; Bossert I; Matti A; Schiavina R; Fiorentino M; Romagnoli D; Fonti C; Lodi F; D'Errico A; Brunocilla E; Porreca A; Fanti S
Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):390-409. PubMed ID: 34213609
[TBL] [Abstract][Full Text] [Related]
28. Papillary Urothelial Carcinoma of Urinary Bladder Identified on 18F-Fluciclovine PET/CT.
Meka VM; Wankhar B; Ojili V; Batchala PP
Clin Nucl Med; 2021 Aug; 46(8):e438-e439. PubMed ID: 33782311
[TBL] [Abstract][Full Text] [Related]
29. Best Practices for
Tade FI; Sajdak RA; Gabriel M; Wagner RH; Savir-Baruch B
J Nucl Med Technol; 2019 Dec; 47(4):282-287. PubMed ID: 31182661
[No Abstract] [Full Text] [Related]
30. PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
Crocerossa F; Carbonara U; Parekh J; Urdaneta A; Weprin S; Damiano R; Grob MB; Hampton LJ; Paul A; Autorino R; Cantiello F
Urol Int; 2022; 106(9):920-927. PubMed ID: 34933313
[TBL] [Abstract][Full Text] [Related]
31. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
[TBL] [Abstract][Full Text] [Related]
32. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of Hyperfunctioning Parathyroid Gland Localization Using [
Akintayo AA; Abiodun-Ojo OA; Weber C; Sharma J; Cohen C; Sica G; Halkar R; Goodman MM; Schuster DM
Mol Imaging Biol; 2019 Oct; 21(5):818-824. PubMed ID: 30617729
[TBL] [Abstract][Full Text] [Related]
34.
Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
[TBL] [Abstract][Full Text] [Related]
35. Phase IIa clinical study of [
Kondo A; Ishii H; Aoki S; Suzuki M; Nagasawa H; Kubota K; Minamimoto R; Arakawa A; Tominaga M; Arai H
Ann Nucl Med; 2016 Nov; 30(9):608-618. PubMed ID: 27418267
[TBL] [Abstract][Full Text] [Related]
36. Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer.
Bach-Gansmo T; Korsan K; Bogsrud TV
Tomography; 2022 Jun; 8(3):1477-1484. PubMed ID: 35736868
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Including Bone in Dixon-Based Attenuation Correction for
Elschot M; Selnæs KM; Johansen H; Krüger-Stokke B; Bertilsson H; Bathen TF
J Nucl Med; 2018 Dec; 59(12):1913-1917. PubMed ID: 29728516
[TBL] [Abstract][Full Text] [Related]
38. Bayesian penalised likelihood reconstruction (Q.Clear) of
Teoh EJ; McGowan DR; Schuster DM; Tsakok MT; Gleeson FV; Bradley KM
Br J Radiol; 2018 May; 91(1085):20170727. PubMed ID: 29303359
[TBL] [Abstract][Full Text] [Related]
39. Fasting Enhances the Contrast of Bone Metastatic Lesions in
Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468238
[No Abstract] [Full Text] [Related]
40. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
